Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

693
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
693
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A pilot translational study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma.

Nature communications·2026
Same author

Immunodominance Hierarchy of Endogenous BBN963 Bladder Cancer Antigens Remains Stable Under Anti-PD1 and Anti-CTLA4 Immunotherapy.

bioRxiv : the preprint server for biology·2026
Same author

Lipid Nanoparticle-encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ Plus Durvalumab Induces an Immunostimulatory Effect Within the Tumor Microenvironment in Patients with Advanced Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL-2 in Patients with High-Grade Serous Ovarian Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Intratumoral sotigalimab with pembrolizumab induces rapid activation of antigen presenting cells and drives anti-tumor responses in non-injected tumors in metastatic melanoma: A phase I/II study.

Cancer discovery·2026

Related Experiment Video

Updated: Sep 28, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K

Hallmarks of Resistance to Immune-Checkpoint Inhibitors.

Maria Karasarides1, Alexandria P Cogdill2,3, Paul B Robbins4

  • 1Worldwide Medical Oncology, Bristol Myers Squibb, Princeton, New Jersey.

Cancer Immunology Research
|April 1, 2022
PubMed
Summary
This summary is machine-generated.

Immune-checkpoint inhibitors (ICIs) show limited efficacy in many cancers. This research outlines a framework of eight biological processes, or "immune resistance nodes," to guide future research and improve patient outcomes.

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

584
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.8K

Related Experiment Videos

Last Updated: Sep 28, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

584
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.8K

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Immune-checkpoint inhibitors (ICIs) have transformed cancer treatment but are ineffective for many patients.
  • Resistance to ICIs is a significant challenge, limiting their widespread clinical benefit.
  • Identifying mechanisms of resistance is crucial for developing more effective cancer therapies.

Purpose of the Study:

  • To establish a framework for understanding and researching immune resistance to ICIs.
  • To identify key biological processes contributing to ICI resistance.
  • To guide future research directions and drug development for overcoming treatment resistance.

Main Methods:

  • A collaborative workshop involving experts from academia, biopharma, and nonprofit sectors.
  • Collating seminal discoveries related to known biological processes.
  • Defining eight "immune resistance nodes" based on biological processes.

Main Results:

  • Identified eight critical biological processes as "immune resistance nodes."
  • Highlighted seminal discoveries defining each node.
  • Posed critical research questions to advance the understanding of immune resistance.

Conclusions:

  • A structured framework for immune resistance research has been proposed.
  • Answering key questions about these nodes will expand our understanding of ICI resistance.
  • Integrating multiomic data can create a map of resistance phenotypes to guide drug development and improve patient outcomes.